Comparison of the Clinical Outcomes Between Cisplatin-Chemoradiotherapy and Radiotherapy Alone in Patient with Cervical Cancer.
- Author:
Jee Hyun LEE
1
;
Jung NAM
;
Jin Hee RHU
;
Jeong Ja KIM
;
Hee Kyung LIM
;
Yong Jae YANG
;
Ki Sung RYU
;
Ku Taek HAN
;
Hun Young LEE
;
Soo Pyung KIM
Author Information
1. Department of Obstetrics and Gynecology, Catholic University, Seoul, Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Chemoradiotherapy
- MeSH:
Chemoradiotherapy;
Cisplatin;
Disease-Free Survival;
Humans;
Radiotherapy*;
Retrospective Studies;
Survival Rate;
Biomarkers, Tumor;
Uterine Cervical Neoplasms*
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1998;9(3):259-265
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We compared the therapeutic effects of concomitant chemoradiotherapy (CRT) using cisplatin to single radiotherapy (RT) in uterine cervical cancer. 34 cases of non-operable uterine cervical cancer were reviewed retrospectively from Mar, 1993 to May, 1996 in St. Mary' s Hospital. The patients were randomly selected to compare the effects of both methods. 22 patients were included in CRT group and 12 patients in RT group. The results were as follows: 1. The decrease of tumor size was not significant (2.17 cm in CRT and 1.95 cm in RT) (p=0.61), but the number of responders of CRT group was larger than that of RT group significantly (p<0.05). 2. The tumor markers showed no significant difference between CRT and RT groups (p>0.05) 3. The overall survival rate showed no difference between two groups (p>0.05). The disease-free survivals for 38 months were 17.02% in CRT and 11.36% in RT, but it was not significant (p>0.05). In conclusion, concomitant chemoradiotherapy showed better rate of response, but size of tumor decrease and tumor markers showed no difference. CRT might improve the overall survival and disease-free survival, although it was not significant in this study. The clinical significance of CRT remains to be determined in large randomized clinical trial.
